دورية أكاديمية
2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis.
العنوان: | 2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis. |
---|---|
المؤلفون: | Al-Rabia MW; Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alfaleh MA; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Asfour HZ; Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Alharbi WS; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., El-Moselhy MA; Clinical Pharmacy and Pharmacology Department, Ibn Sina National College for Medical Studies, Jeddah 21589, Saudi Arabia.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Minia 61519, Egypt., Alhakamy NA; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Fahmy UA; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Ahmed OAA; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Fahmy O; Department of Urology, Universiti Putra Malaysia, Serdang 43400, Malaysia., Rashad OM; Department of Pharmaceutical Technology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt., Alamoudi AJ; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Abdel-Naim AB; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. |
المصدر: | Antioxidants (Basel, Switzerland) [Antioxidants (Basel)] 2022 Jul 30; Vol. 11 (8). Date of Electronic Publication: 2022 Jul 30. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101668981 Publication Model: Electronic Cited Medium: Print ISSN: 2076-3921 (Print) Linking ISSN: 20763921 NLM ISO Abbreviation: Antioxidants (Basel) Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, [2012]- |
مستخلص: | The immunosuppressant cyclosporine A (CSA) has been linked to serious renal toxic effects. Although 2-methoxyestradiol (2ME) possesses a wide range of pharmacological abilities, it suffers poor bioavailability after oral administration. The purpose of this study was to evaluate the potential of 2ME loaded D-ɑ-tocopheryl polyethylene glycol succinate (TPGS) micelles to prevent CSA-induced nephrotoxicity in rats. A 2ME-TPGS was prepared and showed particle size of 44.3 ± 3.5 nm with good entrapment efficiency and spherical structures. Male Wistar rats were divided into 5 groups, namely: Control, Vehicle, CSA, CSA + 2ME-Raw, and CSA + 2ME-Nano. CSA was injected daily at a SC dose of 20 mg/kg. Both 2ME-Raw and 2ME-Nano were given daily at oral doses of 5 mg/kg. Treatments continued for three successive weeks. 2ME-TPGS exerted significant protective effects against CSA nephrotoxicity. This was evidenced in ameliorating deterioration of renal functions, attenuation of pathological changes in kidney tissues, exerting significant anti-fibrotic, antioxidant, and anti-inflammatory effects together with significant anti-apoptotic effects. Western blot analyses showed both 2ME-Raw and 2ME-Nano significantly inhibited protein expression of TGF-β1 and phospho-ERK (p-ERK). It was observed that 2ME-TPGS, in almost all experiments, exerted superior protective effects as compared with 2ME-Raw. In conclusion, 2ME loaded in a TPGS nanocarrier possesses significant protective activities against CSA-induced kidney injury in rats. This is attributable to 2ME anti-fibrotic, antioxidant, anti-inflammatory, and anti-apoptotic activities which are mediated at least partly by inhibition of TGF-β1/p-ERK axis. |
References: | J Med Chem. 2007 Dec 27;50(26):6700-5. (PMID: 18052315) Arch Toxicol. 2017 Apr;91(4):1925-1939. (PMID: 27585667) Colloids Surf B Biointerfaces. 2017 Feb 1;150:242-249. (PMID: 27923186) Mol Med Rep. 2018 Apr;17(4):6038-6044. (PMID: 29436671) Prog Histochem Cytochem. 2004;39(2):85-128. (PMID: 15354618) Naunyn Schmiedebergs Arch Pharmacol. 2019 Mar;392(3):381-391. (PMID: 30535572) Br J Cancer. 2004 Feb 23;90(4):932-7. (PMID: 14970876) Transplant Proc. 2004 Mar;36(2 Suppl):229S-233S. (PMID: 15041343) J Colloid Interface Sci. 2021 Jan 15;582(Pt A):353-363. (PMID: 32858401) Dose Response. 2021 Dec 9;19(4):15593258211055023. (PMID: 34987331) Naunyn Schmiedebergs Arch Pharmacol. 2022 Apr;395(4):387-395. (PMID: 35092471) Braz J Med Biol Res. 2017 Dec 11;51(2):e6373. (PMID: 29267497) Front Bioeng Biotechnol. 2022 May 13;10:870049. (PMID: 35646840) Vascul Pharmacol. 2009 Aug-Sep;51(2-3):190-7. (PMID: 19540933) Transplantation. 1987 Jul;44(1):135-41. (PMID: 3603674) Front Pharmacol. 2021 Jul 16;12:682337. (PMID: 34335251) Transplant Proc. 2004 Mar;36(2 Suppl):234S-239S. (PMID: 15041344) Invest New Drugs. 2011 Dec;29(6):1465-74. (PMID: 20499131) Front Immunol. 2021 Mar 16;12:596376. (PMID: 33796096) Fundam Clin Pharmacol. 2011 Oct;25(5):619-26. (PMID: 21077939) Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61. (PMID: 21464325) Kidney Blood Press Res. 2019;44(4):656-668. (PMID: 31387101) Rapid Commun Mass Spectrom. 2005;19(9):1176-82. (PMID: 15818726) Eur J Pharm Sci. 2013 May 13;49(2):175-86. (PMID: 23485439) J Drug Target. 2011 May;19(4):270-80. (PMID: 20608785) Hypertension. 2021 Nov;78(5):1368-1381. (PMID: 34628937) Environ Toxicol Pharmacol. 2019 Jul;69:26-35. (PMID: 30927701) Kidney Int. 1995 Nov;48(5):1487-96. (PMID: 8544405) Kidney Int. 2006 Dec;70(11):1914-9. (PMID: 16985515) Am J Transplant. 2005 Aug;5(8):1856-67. (PMID: 15996232) Toxicol Appl Pharmacol. 2013 Nov 1;272(3):825-41. (PMID: 23958496) Methods Find Exp Clin Pharmacol. 2001 May;23(4):175-81. (PMID: 11676225) Maturitas. 2008 Dec 20;61(4):310-6. (PMID: 19010616) Life Sci. 2022 May 1;296:120441. (PMID: 35240160) Am J Kidney Dis. 1996 Nov;28(5):631-67. (PMID: 9158202) Clin Cancer Res. 2009 Feb 15;15(4):1460-5. (PMID: 19228747) Invest New Drugs. 2007 Feb;25(1):41-8. (PMID: 16969706) Exp Ther Med. 2017 May;13(5):2537-2543. (PMID: 28565876) Mol Pharm. 2013 May 6;10(5):2062-70. (PMID: 23557122) Food Chem Toxicol. 2018 Aug;118:889-907. (PMID: 29960018) Hum Exp Toxicol. 2011 Feb;30(2):145-51. (PMID: 20488842) Clin Kidney J. 2017 Dec;10(6):747-758. (PMID: 29225803) Theranostics. 2018 Jan 1;8(2):464-485. (PMID: 29290821) Ann Intern Med. 1984 Nov;101(5):667-82. (PMID: 6385799) BMC Pharmacol. 2005 Oct 15;5:15. (PMID: 16225695) Adv Chronic Kidney Dis. 2021 Sep;28(5):402-414.e1. (PMID: 35190107) Immunopharmacology. 2000 May;47(2-3):119-25. (PMID: 10878286) Invest New Drugs. 2012 Apr;30(2):794-802. (PMID: 21174224) Toxicol Res. 2010 Sep;26(3):163-70. (PMID: 24278520) Eur J Pharm Biopharm. 2017 Dec;121:97-103. (PMID: 28958946) Biology (Basel). 2021 May 17;10(5):. (PMID: 34067576) Biomed Res Int. 2014;2014:431524. (PMID: 25229058) Nutrients. 2022 Feb 09;14(4):. (PMID: 35215383) J Cardiovasc Pharmacol. 2007 Jan;49(1):56-63. (PMID: 17261964) Adv Healthc Mater. 2015 Sep 16;4(13):2037-45. (PMID: 26121684) Kidney Int. 1999 Feb;55(2):674-85. (PMID: 9987092) Environ Sci Pollut Res Int. 2022 Aug;29(39):59524-59533. (PMID: 35384535) Cancer Metastasis Rev. 2000;19(1-2):173-9. (PMID: 11191057) Kidney Int. 1996 Oct;50(4):1089-100. (PMID: 8887265) Front Cell Neurosci. 2022 Apr 26;16:869546. (PMID: 35558877) Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. (PMID: 19218475) Pharmacotherapy. 2003 Feb;23(2):165-72. (PMID: 12587805) J Zhejiang Univ Sci B. 2019 Mar.;20(3):273-281. (PMID: 30829014) Biomaterials. 2013 Apr;34(13):3411-21. (PMID: 23375951) Sci Rep. 2017 Jun 7;7(1):2964. (PMID: 28592843) N Engl J Med. 1984 Sep 13;311(11):699-705. (PMID: 6382005) Oxid Med Cell Longev. 2018 Aug 1;2018:4389484. (PMID: 30154949) Front Immunol. 2019 Mar 28;10:588. (PMID: 30984176) Transplantation. 1986 Aug;42(2):154-8. (PMID: 3526655) Nephrol Dial Transplant. 2001;16 Suppl 1:121-4. (PMID: 11369839) Int J Pharm. 2017 Aug 30;529(1-2):506-522. (PMID: 28711640) Int J Nanomedicine. 2019 Jul 23;14:5555-5567. (PMID: 31413562) Fertil Steril. 2012 Jul;98(1):178-84. (PMID: 22579131) Reprod Sci. 2013 Sep;20(9):1020-9. (PMID: 23456663) J Transplant. 2012;2012:230386. (PMID: 22263104) Pharmaceuticals (Basel). 2021 Mar 04;14(3):. (PMID: 33806321) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Adv Chronic Kidney Dis. 2013 Nov;20(6):454-65. (PMID: 24206598) Eur J Pharmacol. 2020 Sep 5;882:173278. (PMID: 32544503) J Am Soc Nephrol. 2010 Aug;21(8):1254-62. (PMID: 20651166) Reprod Sci. 2012 Oct;19(10):1018-29. (PMID: 22875846) Biomol Ther (Seoul). 2012 May;20(3):268-72. (PMID: 24130922) Br Med J (Clin Res Ed). 1981 Mar 21;282(6268):934-6. (PMID: 6781658) Eur J Pharm Biopharm. 2017 Apr;113:211-228. (PMID: 28087380) Hypertension. 2017 Jun;69(6):1104-1112. (PMID: 28416584) J Thorac Cardiovasc Surg. 2005 Sep;130(3):662-9. (PMID: 16153910) AORN J. 1998 Nov;68(5):800, 803-16, 819-20; quiz 821-4. (PMID: 9829131) J Diabetes Res. 2013;2013:463740. (PMID: 23936866) Toxicol Appl Pharmacol. 2009 Sep 15;239(3):241-50. (PMID: 19523970) J Biol Chem. 2000 Sep 8;275(36):27650-6. (PMID: 10862759) J Vis Exp. 2013 Dec 27;(82):51015. (PMID: 24429733) Shock. 2011 Nov;36(5):510-6. (PMID: 21841536) Transplant Proc. 2013 Oct;45(8):3127-34. (PMID: 24157049) Contrib Nephrol. 2003;139:44-65. (PMID: 12854318) Drug Deliv. 2022 Dec;29(1):1536-1548. (PMID: 35612292) J Neurochem. 2014 Jun;129(6):940-54. (PMID: 24606183) Pharm Res. 1999 Oct;16(10):1550-6. (PMID: 10554096) Cancer Res. 2006 Jan 1;66(1):324-30. (PMID: 16397246) |
معلومات مُعتمدة: | RG-17-140-42 King Abdulaziz University |
فهرسة مساهمة: | Keywords: 2-methoxyestradiol; TGF-β1; TPGS; cyclosporine A; nephrotoxicity; p-ERK |
تواريخ الأحداث: | Date Created: 20220826 Latest Revision: 20220830 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC9405159 |
DOI: | 10.3390/antiox11081499 |
PMID: | 36009218 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2076-3921 |
---|---|
DOI: | 10.3390/antiox11081499 |